

## antiviral and associated therapy - all results

| Treatment                   | Number of studies      | Demonstrated or suggested results | Inconclusive results   | Uncertain results | Safety results |
|-----------------------------|------------------------|-----------------------------------|--|-------------------|----------------|
| chloroquine and derivatives | 4 studies <sup>1</sup> |                                   | inconclusive results for : death D28 ; deaths ; deaths (time to event analysis only) ; clinical deterioration ; clinical improvement (time to event analysis only) ; hospital discharge ; ICU admission ; off oxygenation  | suggested 86      |                |
| ivermectin                  | 3 studies <sup>2</sup> |                                   | inconclusive results for : deaths ; deaths (time to event analysis only) ; clinical improvement ; clinical improvement (7-day) ; viral clearance ; ICU admission   | suggested 86      |                |
| lopinavir/ritonavir         | 2 studies <sup>3</sup> |                                   | inconclusive results for : deaths ; deaths (time to event analysis only) ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (28-day) ; clinical improvement (7-day) ; clinical improvement (time to event analysis only) ; death or ventilation ; hospital discharge ; serious adverse events |                   |                |
| azithromycin                | 1 study <sup>4</sup>   |                                   | inconclusive results for : death D28 ; deaths ; deaths (time to event analysis only) ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (28-day) ; clinical improvement (7-day) ; related SAE (TRSAE) ; serious adverse events ; long QT ; renal impairment                                   |                   |                |
| favipiravir                 | 1 study <sup>5</sup>   |                                   | inconclusive results for : deaths ; hospital discharge   |                   |                |

Continued on next page

| Treatment                                   | Number of studies    | Demonstrated or suggested results | Inconclusive results   | Uncertain results | Safety results |
|---|----------------------|-----------------------------------|--|-------------------|----------------|
| Lopinavir/ritonavir plus hydroxychloroquine | 1 study <sup>6</sup> |                                   | inconclusive results for : clinical improvement ; clinical improvement (14-day) ; hospital discharge ; serious adverse events  | suggested 42      |                |
| remdesivir                                  | 1 study <sup>7</sup> |                                   | inconclusive results for : deaths ; clinical deterioration ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (28-day) ; clinical improvement (7-day) ; clinical improvement (time to event analysis only) ; AE leading to drug discontinuation ; serious adverse events ; deep vein thrombosis ; elevated liver enzymes ; hyperbilirubinemia ; pulmonary embolism ; renal impairment |                   |                |
| sofosbuvir and daclatasvir                  | 1 study <sup>8</sup> |                                   | inconclusive results for : adverse events  | suggested 88      |                |

Uncertain results are statistically significant results but obtain in trial with high risk of bias.

Demonstrated results are significant results obtained on the primary endpoint of a trial at low risk of bias or with some concerns.

## Notes

<sup>1</sup>HYDRA (Hernandez-Cardenas), 2021 (NCT04315896) ; REMAP-CAP-HCQ, 2020 (NCT02735707) ; Mahevas, 2020 () ; Yu, 2020 ()

<sup>2</sup>Galan, 2021 (RBR-8h7q82) ; Okumus, 2020 (NCT04646109) ; Camprubi, 2020 ()

<sup>3</sup>Cao, 2020 (ChiCTR2000029308) ; REMAP-CAP (lopinavir/ritonavir only), 2020 (NCT02735707)

<sup>4</sup>COALITION II Covid-19 Brazil (Furtado), 2020 (NCT04321278)

<sup>5</sup>Kocayigit H, 2020 ()

<sup>6</sup>REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 (NCT02735707)

<sup>7</sup>CAP-China (Wang et al.), 2020 (NCT04257656)

<sup>8</sup>Eslami, 2020 (IRCT20200324046850N2)